Convexia Analysis: $500K Raised
What is Convexia?
Convexia is an AI-maximalist pharma company focused on uncovering overlooked drug assets. Their approach integrates specialized AI agents with expert human review, streamlining the drug development process. This enables faster identification and evaluation of high-potential therapeutics, transforming traditional drug sourcing methods.
Employees
1-10
Founded
2025
Industry
AI/ML, HealthTech, Biotech
Latest Funding Round Size
$500,000
YC Batch
S25
Yc Partner
Ankit Gupta
Product Features & Capabilities
- Asset Discovery Agent for global drug asset scanning
- Scientific Evaluation Stack with over 50 custom models
- Specialist Human Review by domain experts
- Market Insight Agent for competitive analysis
- Operational Risk Agent for trial risk assessment.
Use Cases
Identify overlooked drug assets for development; Evaluate drug candidates using in silico simulations; Assess market potential and competitive landscape; Validate scientific data through expert review; Package assets for pharma partnerships.
How much Convexia raised
Funding Round - $500,000
RecentWho are the founders of Convexia
AP
Ayaan Parikh
Co-Founder
DL
David Lozano
CEO
Other Considerations
Backed by Stanford and Y Combinator; Collaborates with CROs for clinical trials; Focuses on AI-driven drug lifecycle management.
See something that needs updating? Suggest edits to this profile.